Biotechnology company Moderna announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, the company's next generation COVID-19 vaccine candidate.
![Moderna Starts New COVID-19 Vaccine Trial Moderna Starts New COVID-19 Vaccine Trial](https://images.medindia.net/health-images/1200_1000/cold5.jpg)
‘Phase 1 study of new trial by Moderna will evaluate three dose levels, 10 µg, 30 µg, and 100 µg, of the mRNA-1283 COVID-19 vaccine candidate given to healthy adults as a 2-dose series, 28 days apart.’
Read More..
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
"Our investments in our mRNA platform have enabled us to develop this next generation vaccine candidate, which is a potential refrigerator-stable vaccine that could facilitate easier distribution and administration in a wider range of settings, including potentially for developing countries," Bancel added. Read More..
![twitter](https://images.medindia.net/icons/news/social/twitter.png)
![facebook](https://images.medindia.net/icons/news/social/facebook.png)
![whatsapp](https://images.medindia.net/icons/news/social/whatsapp.png)
![linkedin](https://images.medindia.net/icons/news/social/linkedin.png)
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
mRNA-1283 encodes for the portions of the SARS-CoV-2 spike protein critical for neutralization, specifically the Receptor Binding Domain (RBD) and N-terminal Domain (NTD).
This Phase 1 study will evaluate three dose levels, 10 µg, 30 µg, and 100 µg, of the mRNA-1283 vaccine candidate given to healthy adults as a 2-dose series, 28 days apart, and one dose level, 100 µg, of mRNA-1283 given to healthy adults in a single dose, the company said.
These will be compared with a 2-dose series of 100 µg of mRNA-1273, the currently authorized dose level.
mRNA-1283 is intended to be evaluated in future studies for use as a booster dose for previously vaccinated or seropositive as well as in a primary series for seronegative individuals.
Advertisement
Source-IANS